<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
NAME OF ISSUER: AMARILLO BIOSCIENCES, INC.
TITLE OF CLASS OF SECURITIES: Common Stock, par value $.01 per share
CUSIP NUMBER: 02301P106
NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE NOTICES
AND COMMUNICATIONS: MORRIS MOORE MOSS & DOUGLASS, P.C., P. O. Box
15208, Amarillo, Texas 79105; 806/374-9551
DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: April 2, 1999
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box. [ ]
Note. Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See Rule
13d-7(b) for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
<PAGE> 2
CUSIP No. 02301P106
1. NAME OF REPORTING PERSON: Hayashibara Biochemical Laboratories, Inc.
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
(a) [ ]
(b) [ ]
3. SEC USE ONLY:
4. SOURCE OF FUNDS: OO
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) OR 2(e): [ ]
6. CITIZENSHIP OR PLACE OF ORGANIZATION: Japan
7. SOLE VOTING POWER: 2,178,950 shares
8. SHARED VOTING POWER:
9. SOLE DISPOSITIVE POWER: 2,178,950 shares
10. SHARED DISPOSITIVE POWER:
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:
2,178,950 shares
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS): [ ]
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 34.3%
14. TYPE OF REPORTING PERSON: CO
<PAGE> 3
Item 1 SECURITY AND ISSUER:
This statement relates to shares of common stock, par value
$.01 per share (the "Stock"), of Amarillo Biosciences, Inc., a
Texas corporation (the "Issuer"). The principal executive
offices of the Issuer are located at 800 West 9th, Amarillo,
Texas 79101.
Item 2 IDENTITY AND BACKGROUND:
Hayashibara Biochemical Laboratories, Inc. ("HBL") is a
Japanese corporation whose principal business is research,
development, patent development, and licensing in biochemical
life sciences and nutrition fields. The principal office of
HBL is Hayashibara Company, Ltd., 2-3 Shimoishii, 1-chome,
Okayama, 700 Japan. HBL has not been involved in any criminal
or civil proceedings in the past five years.
Item 3 SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION:
In the transaction in question, HBL acquired 946,094 shares in
exchange for releasing debt and accrued interest in the amount
of $2,808,356 owed to HBL by Issuer.
Item 4 PURPOSE OF TRANSACTION:
The purpose of the April 2, 1999 acquisition of the shares of
Issuer by HBL was to eliminate Issuer's expense from interest
on the debt owed to HBL. By eliminating this interest expense,
HBL hopes to assist Issuer in remaining financially viable
until it can complete its research and become profitable.
Item 5 INTEREST IN SECURITIES OF THE ISSUER:
Prior to the reported transaction, HBL owned 1,232,856 shares
out of 5,414,232 outstanding, for an ownership share of 22.8%.
In the transaction, HBL acquired 946,094 shares. Therefore,
HBL now owns 2,178,950 shares out of 6,360,326 outstanding,
for an ownership share of 34.3%.
Item 6 CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH
RESPECT TO SECURITIES OF THE ISSUER:
None
<PAGE> 4
Item 7 MATERIAL TO BE FILED AS EXHIBITS:
None
SIGNATURES
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: April 9, 1999 .
----------------------
HAYASHIBARA BIOCHEMICAL LABORATORY, INC.
By: /s/ KEN HAYASHIBARA
-----------------------------------------
Ken Hayashibara, President
